These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 15178513

  • 1. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.
    Deedwania PC, Hunninghake DB, Bays H.
    Am J Cardiol; 2004 Jun 03; 93(11A):18C-26C. PubMed ID: 15178513
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy.
    Rajaram V, Pandhya S, Patel S, Meyer PM, Goldin M, Feinstein MJ, Neems R, Liebson PR, Fiedler BM, Macioch JE, Feinstein SB.
    Am J Cardiol; 2004 Jun 03; 93(11A):32C-48C. PubMed ID: 15178515
    [Abstract] [Full Text] [Related]

  • 4. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS, Bissonnette S, Habib R, Boukas S, Ezetrol Add-On Investigators.
    Ann Pharmacother; 2007 Sep 03; 41(9):1345-51. PubMed ID: 17666579
    [Abstract] [Full Text] [Related]

  • 5. Diabetes and metabolic syndrome (MS).
    Bellomo A, Mancinella M, Troisi G, Ettorre E, Marigliano V.
    Arch Gerontol Geriatr; 2007 Sep 03; 44 Suppl 1():61-7. PubMed ID: 17317435
    [Abstract] [Full Text] [Related]

  • 6. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov 03; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 7. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep 03; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

  • 8. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M.
    Am J Cardiol; 2008 Dec 22; 102(12A):19L-27L. PubMed ID: 19084086
    [Abstract] [Full Text] [Related]

  • 9. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL.
    Clin Ther; 2007 Jan 22; 29(1):196-209. PubMed ID: 17379061
    [Abstract] [Full Text] [Related]

  • 10. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 11. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 22; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
    Leiter LA, Martineau P, de Teresa E, Farsang C, Gaw A, Gensini G, Langer A, ACTFAST 1 & 2 investigators.
    J Fam Pract; 2008 Oct 22; 57(10):661-8. PubMed ID: 18842192
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 22; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 17. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 22; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 18. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb 22; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.